Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · FY 2026

Enanta Pharmaceuticals FY 2026 Results: Net Loss of $68.2M, Loss Narrows

Enanta Pharmaceuticals reported $194.5 million in cash and marketable securities as of September 30, 2026, providing a runway into fiscal 2029. The company is advancing multiple clinical-stage programs in RSV and immunology, with topline data from its zelicapavir Phase 2b/3 and Phase 2b studies expected in 2027.

FY 2026 at a glance · $ million · annual
MetricFY 2026FY 2025
Revenue63.065.3
Profit before tax-68.2-83.5
Net income-68.2-81.9
EPS (diluted, $ a share)$-2.35$-3.84

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-3.6%
Operating margin-99.0%
Source

10-K filed with the SEC, NASDAQ: ENTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Enanta Pharmaceuticals Inc: key numbers

Share price
$8.69Close, Nov 17
Market cap
$253M
Shares outstanding
29.13MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Enanta Pharmaceuticals Inc

All →
4:29 PM ET 8-K
Financial Results

Enanta Pharmaceuticals Financial Results

Enanta Pharmaceuticals reported fiscal fourth quarter 2026 revenue of $12.9 million and a net loss of $28.3 million, driven by royalty revenue from AbbVie's HCV regimen. The company highlighted clinical progress in its RSV and immunology pipelines, including the completion of enrollment for its Phase 2b LOTUS trial. Enanta also announced the planned retirement of CEO Jay R. Luly by February 2027.

Counterparty
AbbVie

“During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027. We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027.”

Jay R. Luly, Ph.D., President and Chief Executive Officer

“In parallel, we are advancing a growing immunology portfolio focused on developing best-in-class oral medicines that have the potential to raise the standard of care across multiple immune-mediated diseases. We expect to complete dosing in the EDP-978 Phase 1 trial by year-end 2026 and now plan to report data in the first quarter of 2027.”

Jay R. Luly, Ph.D., President and Chief Executive Officer
4:05 PM ET 8-K
Court & Legal Update

Enanta Pharmaceuticals Court & Legal Update

The Unified Patent Court (UPC) of the European Union ruled that Enanta's European Patent No. EP 4 051 265 is invalid, dismissing Enanta's patent infringement action against Pfizer. The lawsuit concerned Pfizer's manufacture and sale of Paxlovid in 18 EU member states. Enanta had sought a determination of liability for infringement, but the court found the infringement action unfounded following its decision on patent validity.

Counterparty
Pfizer Inc.
7:15 AM ET 8-K
Leadership Change

Enanta Pharmaceuticals Leadership Change

Jay R. Luly, Ph.D., has announced his intention to retire as President and CEO of Enanta Pharmaceuticals by February 1, 2027, after 23 years of leadership. Simultaneously, the company appointed Tara L. Kieffer, Ph.D., to the newly created role of Chief Operating Officer to drive operational execution and strategic alignment.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.